Adagio Medical Holdings ( (ADGM)) just unveiled an update. On April 26, 2026, Adagio Medical reported positive six‑month pivotal results from its FULCRUM‑VT IDE trial of the vCLAS ventricular ablation ...

In the single-arm FULCRUM-VT trial, 59% of patients remained free of recurrent VT at 6 months, with less amiodarone use.

Adagio Medical reports positive pivotal results for vCLAS Ventricular Ablation System: Laguna Hills, California Tuesday, April 28, 2026, 17:00 Hrs [IST] Adagio Medical Holdings, I ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation ...

Adagio Medical (Nasdaq:ADGM) today announced new six-month results from its FULCRUM-VT clinical trial evaluating its ablation ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation ...

The trial is evaluating the vCLAS cryoablation system at 20 centres across Canada and the US.

Over the last weekend, Chicago played host to the 2026 edition of the Heart Rhythm Society's annual conference (HRS 2026).

Medtronic announces key Affera clinical study milestones for Sphere-9 and Sphere-360 catheters as global adoption continues: Galway, Ireland Tuesday, April 28, 2026, 11:00 Hrs [IS ...

Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic ventricular tachycardia (VT)Breakthrough device designation granted for use of th ...

Boston Scientific, Abbott and Medtronic shared new cardiac device data at the annual Heart Rhythm Society meeting, where ...

New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large ...